| Autor: |
Barry S. Taylor, Ingo K. Mellinghoff, Lisa M. DeAngelis, Marc Rosenblum, Cameron W. Brennan, Viviane S. Tabar, Timothy A. Chan, Philip H. Gutin, Alexandra M. Miller, Anna F. Piotrowski, Mariza Daras, Adrienne Boire, Christian Grommes, Jacqueline B. Stone, Eli L. Diamond, Thomas J. Kaley, Igor T. Gavrilovic, Antonio Omuro, Elena Pentsova, Craig P. Nolan, T. Jonathan Yang, Kathryn Beal, Allison Hyde, Malbora Manne, Andrew T. McKeown, Shweta S. Chavan, Shahiba Q. Ogilvie, Maryam Pourmaleki, Juliann Chmielecki, Michael E. Goldberg, Diana Mandelker, Zsofia K. Stadler, Angela G. Arnold, David B. Solit, Marc Ladanyi, Ahmet Zehir, Michael F. Berger, Bob T. Li, David M. Hyman, Natalie M. DiStefano, Robert J. Young, Andrew L. Lin, Philip Jonsson |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1078-0432.22472186 |
| Popis: |
Figure S1: Distribution of systemic therapies received. Figure S2: Number of sequenced samples per patient. Figure S3: Subgroup-defining genomic lesions in IDH-wildtype and -mutant gliomas. Figure S4: Frequency of mutations in primary tumors. Figure S5: Frequency of glioma type-defining genes. Figure S6: Outcome by enhancement and cell-cycle alteration status. Figure S7: Alteration of key functional groups in IDH-WT astrocytic tumors. Figure S8: Cell-cycle alterations and outcome in 1p19q-intact IDH WT tumors. Figure S9: Rate of alkylating therapy-induced hypermutation by WHO class. Figure S10: Frequency of actionable alterations. Figure S11: BRAF hotspot mutations in glioma. Figure S12: MR brain images for three patients receiving MAPK-directed therapy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
